Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

441 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Epigenetic landscape reorganisation and reactivation of embryonic development genes are associated with malignancy in IDH-mutant astrocytoma.
Ghisai SA, van Hijfte L, Vallentgoed WR, Tesileanu CMS, de Heer I, Kros JM, Sanson M, Gorlia T, Wick W, Vogelbaum MA, Brandes AA, Franceschi E, Clement PM, Nowak AK, Golfinopoulos V, van den Bent MJ, French PJ, Hoogstrate Y. Ghisai SA, et al. Among authors: sanson m. Acta Neuropathol. 2024 Oct 9;148(1):50. doi: 10.1007/s00401-024-02811-0. Acta Neuropathol. 2024. PMID: 39382765 Free PMC article.
Epigenetic landscape reorganization and reactivation of embryonic development genes are associated with malignancy in IDH-mutant astrocytoma.
Ghisai SA, van Hijfte L, Vallentgoed WR, Tesileanu CMS, de Heer I, Kros JM, Sanson M, Gorlia T, Wick W, Vogelbaum MA, Brandes AA, Franceschi E, Clement PM, Nowak AK, Golfinopoulos V, van den Bent MJ, French PJ, Hoogstrate Y. Ghisai SA, et al. Among authors: sanson m. bioRxiv [Preprint]. 2024 Mar 20:2024.03.19.585212. doi: 10.1101/2024.03.19.585212. bioRxiv. 2024. Update in: Acta Neuropathol. 2024 Oct 9;148(1):50. doi: 10.1007/s00401-024-02811-0. PMID: 38562747 Free PMC article. Updated. Preprint.
Updated EANO guideline on rational molecular testing of gliomas, glioneuronal, and neuronal tumors in adults for targeted therapy selection - Update 1.
van den Bent MJ, Franceschi E, Touat M, French PJ, Idbaih A, Lombardi G, Rudaà R, Schweizer L, Capper D, Sanson M, Wesseling P, Weller M, Eoli M, Anghileri E, Bielle F, Euskirchen P, Geurts M, Wen PY, Preusser M. van den Bent MJ, et al. Among authors: sanson m. Neuro Oncol. 2024 Oct 10:noae213. doi: 10.1093/neuonc/noae213. Online ahead of print. Neuro Oncol. 2024. PMID: 39387386
Survival Outcomes Associated With First-Line Procarbazine, CCNU, and Vincristine or Temozolomide in Combination With Radiotherapy in IDH-Mutant 1p/19q-Codeleted Grade 3 Oligodendroglioma.
Kacimi SEO, Dehais C, Feuvret L, Chinot O, Carpentier C, Bronnimann C, Vauleon E, Djelad A, Cohen-Jonathan Moyal E, Langlois O, Campone M, Ducloie M, Noel G, Cuzzubbo S, Taillandier L, Ramirez C, Younan N, Menei P, Dhermain F, Desenclos C, Ghiringhelli F, Bourg V, Ricard D, Faillot T, Appay R, Tabouret E, Nichelli L, Mathon B, Thomas A, Tran S, Bielle F, Alentorn A, Iorgulescu JB, Boëlle PY, Labreche K, Hoang-Xuan K, Sanson M, Idbaih A, Figarella-Branger D, Ducray F, Touat M; POLA Network. Kacimi SEO, et al. Among authors: sanson m. J Clin Oncol. 2024 Oct 2:JCO2400049. doi: 10.1200/JCO.24.00049. Online ahead of print. J Clin Oncol. 2024. PMID: 39356975
Olaparib in recurrent isocitrate dehydrogenase mutant high-grade glioma: A phase 2 multicenter study of the POLA Network.
Esparragosa Vazquez I, Sanson M, Chinot OL, Fontanilles M, Rivoirard R, Thomas-Maisonneuve L, Cartalat S, Tabouret E, Appay R, Bonneville-Levard A, Darlix A, Meyronet D, Barritault M, Gueyffier F, Remontet L, Maucort-Boulch D, Honnorat J, Dehais C, Ducray F; POLA Network. Esparragosa Vazquez I, et al. Among authors: sanson m. Neurooncol Adv. 2024 May 27;6(1):vdae078. doi: 10.1093/noajnl/vdae078. eCollection 2024 Jan-Dec. Neurooncol Adv. 2024. PMID: 38855053 Free PMC article.
Epstein-Barr virus and immune status imprint the immunogenomics of non-Hodgkin lymphomas occurring in immune-suppressed environments.
Baron M, Labreche K, Veyri M, Désiré N, Bouzidi A, Seck-Thiam F, Charlotte F, Rousseau A, Morin V, Nakid-Cordero C, Abbar B, Picca A, Le Cann M, Balegroune N, Gauthier N, Theodorou I, Touat M, Morel V, Bielle F, Samri A, Alentorn A, Sanson M, Roos-Weil D, Haioun C, Poullot E, De Septenville AL, Davi F, Guihot A, Boelle PY, Leblond V, Coulet F, Spano JP, Choquet S, Autran B. Baron M, et al. Among authors: sanson m. Haematologica. 2024 Nov 1;109(11):3615-3630. doi: 10.3324/haematol.2023.284332. Haematologica. 2024. PMID: 38841782 Free PMC article.
TARGET: A phase I/II open-label multicenter study to assess safety and efficacy of fexagratinib in patients with relapsed/refractory FGFR fusion-positive glioma.
Picca A, Di Stefano AL, Savatovsky J, Ducray F, Chinot O, Moyal EC, Augereau P, Le Rhun E, Schmitt Y, Rousseaux N, Yepnang AMM, Estellat C, Charbonneau F, Letourneur Q, Branger DF, Meyronet D, Fardeau C, Mokhtari K, Bielle F, Iavarone A, Sanson M. Picca A, et al. Among authors: sanson m. Neurooncol Adv. 2024 May 20;6(1):vdae068. doi: 10.1093/noajnl/vdae068. eCollection 2024 Jan-Dec. Neurooncol Adv. 2024. PMID: 38813112 Free PMC article.
441 results